Short Reads | GenomeWeb

Short Reads

Premium

BGI-Shenzhen has announced that it is purchasing Complete Genomics in a deal estimated to be worth about $117.6 million. Under the terms of the merger, BGI will pay $3.15 per share in cash for Complete -Genomics. Complete Genomics will continue to operate as a separate company and remain in Mountain View, Calif., the firms say. Since the announcement, a number of lawsuits have been filed to block the sale, citing a breach of fiduciary duties.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.